Drug intelligence / Profile preview

Dendrophilin

Development stage: Preclinical
Lead developer: Innaxon Therapeutics

Overview

Dendrophilin is a biopharmaceutical TLR4 (Toll-like receptor 4) agonist developed by Innaxon Therapeutics for the treatment of cancer. It consists of a highly purified and physicochemically defined lipopolysaccharide (LPS) solution. Dendrophilin acts through the MyD88 signaling pathway to modulate the immune system, specifically enhancing immunogenic cell death and promoting the intratumoral accumulation of interferon-γ-producing T lymphocytes. It is being investigated for use in immunochemotherapy, particularly in synergy with anthracyclines, and as a vaccine adjuvant to boost immune responses against tumor antigens.

Brand names: Dendrophilin

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on Dendrophilin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dendrophilin.

Explore the full profile